India vs Moldova: Average cost of drugs for extensively drug-resistant tuberculosis
India
1,203 constant 2022 US$
in 2024
Moldova
1,400 constant 2022 US$
in 2024
India rank
39th
Moldova rank
36th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- India
- Moldova
How they compare
Moldova currently reports 1,400 constant 2022 US$ against 1,203 constant 2022 US$ in India, a difference of 197 constant 2022 US$.
That makes Moldova's figure about 1.2 times India's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was India ahead.
India ranks 39th and Moldova ranks 36th of 56 countries.
Across the 2 decades both report, India averaged higher in 1 and Moldova in 1.
Head to head by decade
| Decade | India | Moldova | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,000 constant 2022 US$ | 5,922 constant 2022 US$ | 1,078 constant 2022 US$ | India |
| 2020s | 2,104 constant 2022 US$ | 2,970 constant 2022 US$ | 866.4 constant 2022 US$ | Moldova |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, India or Moldova?
- Moldova, at 1,400 constant 2022 US$ against 1,203 constant 2022 US$ in India as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between India and Moldova?
- 197 constant 2022 US$, with Moldova ahead.
- How many years of comparable data are there for India and Moldova?
- 8 years are reported by both, from 2017 to 2024.
- How do India and Moldova rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- India ranks 39th and Moldova ranks 36th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.